These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26320756)

  • 1. Referral Patterns for Primary Prophylaxis Implantable Cardioverter Defibrillator Therapy for an Urban US Population.
    Manheimer ED; Gonzalez C; Turk J; Krumerman AK; Kim SG; Gross JN; Palma EC; Grushko MJ; Fisher JD; Ferrick KJ
    Am J Cardiol; 2015 Oct; 116(8):1210-2. PubMed ID: 26320756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of Thomas KL; Al-Khatib SM; Kelsey RC; Bush H; Brosius L; Velazquez EJ; Peterson ED; Gilliam FR
    Am J Cardiol; 2007 Sep; 100(6):924-9. PubMed ID: 17826371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Referring physicians' discordance with the primary prevention implantable cardioverter-defibrillator guidelines: a national survey.
    Castellanos JM; Smith LM; Varosy PD; Dehlendorf C; Marcus GM
    Heart Rhythm; 2012 Jun; 9(6):874-81. PubMed ID: 22306794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators.
    Sadarmin PP; Wong KC; Rajappan K; Bashir Y; Betts TR
    Europace; 2014 Nov; 16(11):1575-9. PubMed ID: 24668515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a 2012 calculation for a midwestern health referral region.
    Hoang A; Shen C; Zheng J; Taylor S; Groh WJ; Rosenman M; Buxton AE; Chen PS
    Heart Rhythm; 2014 May; 11(5):849-55. PubMed ID: 24566233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low referral pattern for implantable defibrillator therapy in a tertiary hospital: referral physician survey and Monte Carlo simulation.
    Mohamad T; Jacob S; Kommuri NV; Modi S; Aravindhakshan R; Lieberman R
    Am J Ther; 2011 Sep; 18(5):350-4. PubMed ID: 20335787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparities in the use of primary prevention and defibrillator therapy among blacks and women.
    Gauri AJ; Davis A; Hong T; Burke MC; Knight BP
    Am J Med; 2006 Feb; 119(2):167.e17-21. PubMed ID: 16443424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients.
    Lee JH; Yu HT; Oh IY; Choi EK; Sung JH; Lee YS; Kim JY; Baek Y; Park J; Joung B;
    Yonsei Med J; 2020 Nov; 61(11):942-950. PubMed ID: 33107237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a screening tool improves appropriate referral to an electrophysiologist for implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.
    Gravelin LM; Yuhas J; Remetz M; Radford M; Foley J; Lampert R
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):152-6. PubMed ID: 21304093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter defibrillator and survival after out-of-hospital cardiac arrest due to acute myocardial infarction in Denmark in the years 2001-2012, a nationwide study.
    Winther-Jensen M; Kjaergaard J; Lassen JF; Køber L; Torp-Pedersen C; Hansen SM; Lippert F; Kragholm K; Christensen EF; Hassager C
    Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):144-154. PubMed ID: 28058848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community.
    Narayanan K; Reinier K; Uy-Evanado A; Teodorescu C; Chugh H; Marijon E; Gunson K; Jui J; Chugh SS
    Circulation; 2013 Oct; 128(16):1733-8. PubMed ID: 24048201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
    Marzec LN; Peterson PN; Bao H; Curtis JP; Masoudi FA; Varosy PD; Bradley SM
    JAMA Cardiol; 2017 May; 2(5):561-565. PubMed ID: 28122073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients.
    Pokorney SD; Hellkamp AS; Yancy CW; Curtis LH; Hammill SC; Peterson ED; Masoudi FA; Bhatt DL; Al-Khalidi HR; Heidenreich PA; Anstrom KJ; Fonarow GC; Al-Khatib SM
    Circ Arrhythm Electrophysiol; 2015 Feb; 8(1):145-51. PubMed ID: 25504649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
    Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
    Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Referring patients for consideration of device treatment of sudden cardiac death and heart failure: incorporating evidence-based therapies within the Canadian health care system.
    Gillis AM
    Can J Cardiol; 2005 May; 21 Suppl A():25A-30A. PubMed ID: 15953941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consideration of patient age and life expectancy in implantable cardioverter-defibrillator referral.
    Dewland TA; Hsu JC; Castellanos JM; Smith LM; Marcus GM
    Am Heart J; 2013 Jul; 166(1):164-70. PubMed ID: 23816036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.